1 The eect of S 15535 (4-benzodioxan-5-yl)1-(indan-2-yl)piperazine), an agonist at presynaptic and antagonist at postsynaptic 5-HT 1A receptors, on the impairment of spatial learning caused by intrahippocampal scopolamine in a two-platform spatial discrimination task was studied. 2 Scopolamine (4.0 mg ml 71 ), injected bilaterally into the CA1 region of the dorsal hippocampus 10 min before each training session, impaired choice accuracy with no eect on choice latency and errors of omission. 3 Administered subcutaneously 30 min before each training session, S 15535 1.0 (but not 0.3) mg kg 71 did not modify choice accuracy but prevented its impairment by intrahippocampal scopolamine. 4 WAY 100635, a 5-HT 1A receptor antagonist, injected into the dorsal raphe at 1.0 mg 0.5 ml 71 5 min before scopolamine, had no eect on choice accuracy and latency or errors of omission and did not modify the eect of scopolamine but completely antagonized the eect of S 15535 (1.0 mg kg 71 ) on scopolamine-induced impairment of choice accuracy. 5 The results con®rm a previous report (Carli et al., 1998) that stimulation of presynaptic 5-HT 1A receptors in the dorsal raphe counteracts the de®cit caused by intrahippocampal scopolamine, probably by facilitating the transfer of facilitatory information from the entorhinal cortex to the hippocampus. 6 Drugs that stimulate action on presynaptic 5-HT 1A receptors, such as S 15535 and other partial 5-HT 1A receptors agonists, may be useful in the symptomatic treatment of human memory disturbances associated with loss of cholinergic innervation to the hippocampus.
Introduction
The density of serotonin 1A (5-HT 1A ) and muscarinic receptors is high in the CA1 region of the dorsal hippocampus (Pazos et al., 1988; Yamamura & Snyder, 1974) , an area traditionally linked with cognitive function, particularly spatial memory, at least in rodents (Morris et al., 1982; O'Keefe & Nadel, 1978) . Electrophysiological studies have shown that stimulation of 5-HT 1A and muscarinic receptors causes respectively hyperpolarization and excitation of hippocampal pyramidal cells (Andrade & Nicoll, 1987; Bernardo & Prince, 1981; Colino & Halliwell, 1987; Segal, 1982) . These ®ndings suggest that 5-HT 1A and muscarinic cholinergic receptors in the dorsal hippocampus have opposite functions in regulating spatial learning in rats.
A series of studies in our laboratory have in fact shown that stimulation of 5-HT 1A receptors and blockade of muscarinic receptors in the CA1 region of the dorsal hippocampus impair spatial learning in a two-platform spatial discrimination task, with no eect on motor/motivational performance or nonspatial visual learning 1995a; 1997b) . The impairment of spatial learning by intrahippocampal scopolamine was prevented by blockade of hippocampal 5-HT 1A receptors (Carli et al., 1995b; 1997a) , so the loss of cholinergic excitatory input on pyramidal cells may be compensated by blockade of the inhibitory 5-HT 1A receptors.
A similar conclusion was reached by Harder et al. (1996) in a study in which blockade of 5-HT 1A receptors by WAY 100635, a potent 5-HT 1A receptor antagonist (Forster et al., 1995) , improved the cognitive de®cit caused by transection of the fornix in the marmoset.
The 5-HT 1A receptors are heterogeneously distributed in the central nervous system and their density is high in the nucleus raphe dorsalis (Pazos et al., 1988) where they act as presynaptic somatodendritic 5-HT receptors (Sprouse & Aghajanian, 1986) . Stimulation of presynaptic 5-HT 1A receptors in the dorsal raphe reversed the de®cit of spatial learning caused by intrahippocampal scopolamine (Carli et al., 1998) , probably by facilitating the transfer of facilitatory information to the hippocampus. On the basis of these and previous ®ndings it was suggested that partial agonists such as buspirone, gepirone, ipsapirone and others which behave as full agonists and antagonists respectively at pre and postsynaptic 5-HT 1A receptors (Sprouse & Aghajanian, 1986) may be useful in the symptomatic treatment of memory disturbances associated with loss of hippocampal cholinergic transmission.
A particularly interesting compound is S 15535 (4-benzodioxan-5-yl)1-(indan-2-yl)piperazine) which behaves as a highly selective, potent antagonist at postsynaptic 5-HT 1A receptors and as an agonist at 5-HT 1A autoreceptors (Millan et al., 1993; . In the present study we examined whether systemically administered S 15535 prevented the scopolamineinduced de®cit in spatial learning. To clarify the role of presynaptic 5-HT 1A receptors, in one experiment we studied the ability of systemically administered S 15535 to prevent the scopolamine-induced de®cit in rats that had received WAY 100635 in the nucleus raphe dorsalis.
As in previous studies Carli et al., 1995a,b; 1997a,b; , we used a two-platform discrimination task in a water maze in which changes in motor or motivational performance are minimized by measuring choice accuracy and latency separately, and motivational changes can be deduced from the number of omissions. Correct performance of the task obliges the rats to use spatial mapping abilities, as shown by the fact that drawing a black curtain around the pool to hide all the extra-maze cues completely blocks acquisition of the task (Morris et al., 1986 ; our unpublished results).
Methods

Animals
Male Crl:CD(SD)BR rats (Charles River, Italy) were housed in groups of ten in standard laboratory conditions (temperature 20+18C and 60% relative humidity) in a room illuminated from 07.00 to 19.00 h. Food and water were freely available.
Procedures involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with the national (D.L. n. 116, G.U., suppl., 40, 18 Febbraio 1992 , Circolare No. 8, G.U., 14 luglio 1994 and international laws and policies (EEC Council Directive 86/609, OJ L 358,1, Dec. 12, 1987 ; Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996) .
Cannula implantation and histology
The rats, anaesthetized with Equithesin (9.7 mg ml 71 sodium pentobarbital in saline +42.6 mg ml 71 chloral hydrate in propylenglycol +21.2 mg ml
71
Mg 2 SO 4 in ethanol; 3.0 ml kg 71 i.p.), were immobilized in a Kopf stereotaxic instrument. The skin was cut and the skull cleaned for implantation of guide cannulae made of 23-gauge stainless steel tubing, 2 mm above the sites to be injected. The guide tubes were secured by acrylic dental cement anchored to three stainless steel screws ®xed to the skull. To prevent clogging, 30-gauge stainless steel stylets were placed in the guide cannulae until the animals were given intracerebral injections.
A single guide cannula was implanted to give access to the dorsal raphe (DR) nucleus. It was positioned at an angle of 208 relative to the saggital plan to avoid damage to the sinus. The coordinates calculated from the interaural line were A, +1.1 mm; L, 71.4 mm; H, +3.2 (Paxinos & Watson, 1982) . To gain access to the CA1 region of the dorsal hippocampus bilateral guide cannulae were implanted at coordinates calculated from the interaural line: A=+5.2 mm L=+2.0 and H=+7.3 (Paxinos & Watson, 1982) . In one experiment rats were simultaneously implanted with three guide cannulae (bilaterally into the CA1 region of the hippocampus and singly into the DR).
After the guide cannulae were implanted the rats were housed singly and were allowed 7 days of recovery. During the last 3 days rats were adapted to the injection procedure by removing each one from its home cage and transporting it to the place where the injection was made. The dummy cannulae were removed and the rat was held ®rmly for 3 min (approximately the time needed for the injection procedure) after which the dummy cannulae were put back. No solutions were infused during these sham injections. On the days of acquisition training the stylets were withdrawn and replaced by injection units (30-gauge stainless steel tubing) terminating 2 mm below the tip of the guides.
On completion of each experiment rats were killed and their brain removed and frozen on dry ice. To check the position of the cannulae tracks, brain sections 40 mm thick were cut in the coronal plane in a Cryo-cut, and the location of the infusion was veri®ed visually. For each experiment only data from rats in which the cannulae were located in the appropriate structures were included in the results.
Some rats were killed and their brains were removed, stored initially in formalin (10%) and then in a sucrose solution (30%). Coronal sections 30 mm thick were cut in the coronal plane in a Cryo-cut, mounted on treated slides and stained with cresyl violet. Representative photographs of the histological sections from animals which received a single injection into the DR and bilateral injections into the CA1 region of dorsal hippocampus on each of the ®ve training days are shown in Figure 1 .
Apparatus
A circular`swimming pool' was used, 1.5 m in diameter and 0.5 m high. The pool was ®lled to a depth of 0.29 m with water (26+18C) rendered opaque by the addition of a food dye (coee colour, Bayo, Italy). The water was changed daily. The pool was placed in the middle of a large room and was surrounded by various visual cues: a blackened window with a big white cross, a white wall with a big black cross, a long table, a door and a picture-covered wall with a rack for cages. The objects could be covered, when required, by black curtains around the maze. When open, the curtains were collected together at one corner of the room, forming another prominent visual cue. The room was lit by a 100 W light bulb in the centre of the ceiling, 2.4 m above the water surface. The light intensity at the water surface was 80 lux (measured by an Illuminometer, Mod 5200, Kyoritsu, Japan).
Two visible platforms were used. The ®xed one protruded 1.5 ± 2.0 cm above the water. Its top was square (11611 cm) and made of Perspex. The second platform also protruded 1.5 ± 2.0 cm above the water and was made of the same material but was ®lled with expanded polystyrene. It was anchored' by thread to a solid movable base on the bottom of the pool. Thus one platform was rigid and provided support, and the other sank when the rats tried to climb onto it.
Training procedure
The black curtains were drawn together to allow a full view of extra-maze cues. Rats were trained to swim to the rigid grey escape platform while avoiding the¯oating grey platform. For all rats, the ®xed escape platform (correct) was always in the same place at the centre of one of the eight sectors. The¯oating platform (incorrect) was positioned over successive trials in a quasi-random sequence of eight locations around the pool, subject to the constraint that the spatial relationship between the platform and the starting position did not consistently reward either right-or leftturning tendencies.
The rats were trained with ten trials a day for 5 days. A trial began with the rat being placed in the pool while held at, and facing, the side wall. Eight possible starting locations were used in quasi-random sequence across trials. A trial ended when the rat escaped onto the rigid platform, where it was allowed to sit for 15 s before being returned to a holding cage until the next trial. The rats were trained in squads of four. Inter-trial intervals were approximately 2 ± 4 min so each daily testing lasted approximately 30 min for each rat. A correct trial was that in which the rats climbed onto the rigid platform without touching the¯oating platform with their forepaws or snout. The occasional incident of brushing past the¯oating platform in passing was not considered an error. If the rat did not choose to escape onto either platform (correct or incorrect) in 60 s it was taken out of the pool and an omission error was scored.
The parameters measured were (1) the ®rst choice in each trial (correct/incorrect), (2) the latency to escape (s), and (3) the number of omissions.
Treatment schedules
After recovery from surgery and adaptation to the injection procedure rats were allocated to dierent treatment groups.
Scopolamine HBr (Sigma, U.S.A.), WAY 100635 (PharmaciaUpjohn, Italy) or saline solutions were delivered at a rate of 0.5 ml min 71 by a Hamilton syringe mounted on a CMA/100 infusion pump (CMA Microdialysis, Stockholm, Sweden), connected by PP10 tubing to a 30-gauge stainless steel cannula (injection unit) terminating 2 mm below the tip of the guides. A total of 0.5 ml of WAY 100635 dissolved in saline, or saline alone, was administered by a single injection into the DR over a 1-min period; bilateral injections of 2 ml scopolamine (dissolved in saline), or saline alone, into the hippocampus were made over 2 min. The injection cannulae were left in place for another minute before withdrawal to allow diusion from the tip and prevent re¯ux of the solution.
Each animal received only one drug regimen given over all testing days.
The number of animals in each group is given here in brackets. In the ®rst experiment, on each acquisition training day, the rats were injected subcutaneously (s.c.) with vehicle 2 ml kg 71 (n=9) or S 15535 (Servier, France) 0.3 mg kg 71 (n=8) or 1.0 mg kg 71 (n=10) dissolved in vehicle (distilled water) and 20 min later they received a bilateral injection 1.0 ml of vehicle into the dorsal hippocampus (stratum radiatum of area CA1). Other rats were injected subcutaneously with 2 ml kg 71 vehicle (n=9), 0.3 mg kg 71 (n=8) or 1.0 mg kg 71 S 15535 (n=9) and bilaterally infused with 4.0 mg ml 71 scopolamine into the hippocampus. In the second experiment rats were injected subcutaneously on each training day with 2 ml kg 71 vehicle and after 15 min injected with either 0.5 ml saline (n=10) or 1.0 mg 0.5 ml 71 WAY 100635 (n=8) into the DR. Other rats were injected subcutaneously with 1.0 mg kg 71 S 15535 followed, 15 min later, by 0.5 ml saline (n=8) or 1.0 mg 0.5 ml 71 WAY 100635 (n=8) into the DR. Five minutes later all animals received a bilateral injection of 4.0 mg ml 71 scopolamine into the dorsal hippocampus.
Control rats (n=9) received 2 ml kg 71 vehicle s.c. followed by a single injection of 0.5 ml saline into the DR and a bilateral injection of 1.0 ml saline into the dorsal hippocampus.
Statistical analysis and measures
Choice accuracy of spatial discrimination was measured as the proportion of correct choices (total correct choices/total correct choices+total incorrect choices). Choice latency was de®ned as the time in seconds taken by the rat to swim from the starting location to either the correct or incorrect platform. For each training day the mean latency to escape was calculated for each rat (total latency/total number of trials). Errors of omission were measured as the number of failures to choose in 60 s. Trials in which the animals made errors of omission were not counted for the measurement of choice accuracy and latency. The eects of s.c. S 15535 on the scopolamine-induced de®cit in accuracy (per cent correct choices) in the two-platform spatial discrimination task were analysed by three-way ANOVA for repeated measures. The ®rst between-subjects factor was S 15535 (three levels), and the second scopolamine (two levels). There were ®ve levels of the repeated within-subjects factor time. Signi®cant threeway interactions between factor S 15535, scopolamine and time were further analysed by two-way ANOVA, examining the eects of factors S 15535 in saline-or scopolaminetreated rats. The interaction between time and factors S 15535 or scopolamine were further analysed by comparing the eects of factors S 15535 or scopolamine for each day separately.
Signi®cant two-way interactions between factor S 15535 and scopolamine were further analysed by comparing treatment group means of the ®ve training sessions, using Tukey's test. The same statistical analysis was applied to choice latencies.
The eects of WAY 100635 injected into the DR on the eect of S 15535 on the scopolamine-induced de®cit in accuracy (per cent correct choices) was examined by threeway ANOVA for repeated measures. The between-subjects factors were S 15535 and WAY 100635. There were ®ve levels of the repeated within subjects factor time. In this experiment one-way ANOVA was used to compare control rats and rats injected with vehicle s.c., saline into the DR and scopolamine into the hippocampus. Post-hoc comparisons between the treatment groups were made for each day separately by Tukey's test. The same statistical analysis was applied to choice latency data.
When required, angular and log10 transformations were done to normalize the distributions in accordance with the ANOVA model (Winer, 1971) .
The analyses of variance for unbalanced data were performed by the general linear model procedure (GLM) using the SAS Institute Inc. (U.S.A.) statistical software run on a Micro VAX 3500 computer (Digital, U.S.A.). The degrees of freedom associated with the F values for the univariate tests of within-subjects eects were adjusted by the GreenhouseGeisser (G-G) epsilon (e). In the result section we have reported only the adjusted Pr4F (G-G) without showing the degrees of freedom of the F values of the repeated factor time. The degrees of freedom of the F values are reported only for the between-subjects factors S 15535, WAY 100635 and their interaction.
The numbers of omissions during the acquisition training were analysed by between-subjects two-way ANOVA.
Results
Histology
Examination of the stained coronal sections showed that multiple injections into the hippocampus and dorsal raphe caused very limited tissue damage in the majority of rats. The degree of gliosis around the injection needle track was similar in all experimental groups. Figure 1 shows some representative photographs of the histological sections of rat brains from the experiment in which the eect of s.c. S 15535 in combination with WAY 100635 injected into the DR was examined in rats injected with scopolamine into the CA1 area of the dorsal hippocampus.
Eects of S 15535 on intrahippocampal scopolamineinduced de®cit
The results on choice accuracy are shown in Figure 2A . The accuracy of rats on the ®rst day of acquisition training was not appreciably dierent, their performance ranging from 50 to 60% of correct choices. The accuracy of the control rats improved each day, reaching about 90% of correct choices on day 5 of training. Rats injected with 4.0 mg ml 71 scopolamine in the CA1 area of the dorsal hippocampus before each acquisition session still showed about 60% of correct choices on the last day of training (time6scopolamine, F=5.03 P=0.001). Injecting the animals with S 15535 had no real eect on any particular day of training (time6S 15535, F=1.04 P=0.40).
ANOVA showed a non-signi®cant three-way interaction time6scopolamine6S 15535 (F=1.25 P=0.27), but a signi®cant two-way interaction between scopolamine and S 15535 (F 2,45 =10.4 P=0.0002), suggesting that, independently of the training day, S 15535 prevented scopolamine-induced impairment of accuracy. The choice accuracy data were further analysed by comparing treatment group means of the ®ve training sessions.
The histograms in Figure 2B present the results as means+s.e.mean of the ®ve training sessions. The post-hoc Tukey's test indicated that saline+scopolamine treated rats had signi®cantly worse discriminative accuracy than controls (saline+saline) (P50.05) and that rats given 1.0 mg kg 71 S 15535+scopolamine had signi®cantly better choice accuracy than those treated with saline+scopolamine (P50.05). S 15535 0.3 mg kg 71 s.c. did not reverse the scopolamineinduced choice accuracy impairment (P40.05). Tukey's test showed that S 15535 by itself had no eect on choice accuracy at any dose tested.
On the ®rst day of training, all rats had the same choice latency ( Figure 2C ) and improved similarly over the 5 days of training. Overall statistical analysis showed no signi®cant three-way (time6scopolamine6S 15535, F=1.65 P=0.13) or two-way interactions between scopolamine and S 15535 (F 1,45 =0.26 P=0.77) or any signi®cant main eect of scopolamine (F 1,45 =0.23 P=0.86) or S 15535 (F 2,45 =0.15 P=0.86) but there was a highly signi®cant main eect of time (F=66.58 P=0.0001).
For the sake of descriptive convenience the acquisition curves of S 15535 0.3 and 1.0 mg kg 71 +saline are not shown in Figure 2A (correct choices) or Figure 2C ( 
Eects of WAY 100635 injected into the DR on the reversal of scopolamine-induced de®cit by S 15535
Since intrahippocampal saline-treated rats given subcutaneous S 15535 (Figure 2 ) or WAY 100635 (1.0 mg 0.5 ml
71
) injected into the DR (Carli et al., 1998) showed no eect on choice accuracy or latency, we examined how WAY 100635 injected into the DR modi®ed the eect of S 15535 on the scopolamineinduced de®cit in accuracy (per cent correct choices) only in the intrahippocampal scopolamine-treated rats. One group of control rats which received saline injected into the hippocampus was used to examine the eects of scopolamine injected into the hippocampus on correct choices and choice latencies.
The results on choice accuracy are shown in Figure 3A . All rats started with 50% correct choices. Rats given saline in the hippocampus improved steadily throughout the training, reaching 85% of correct choices, whereas rats injected with scopolamine into the hippocampus achieved only 55% correct choices at the end of training. The dierence between the mean per cent correct choices of the ®ve training days for the two treatment groups was higly signi®cant (main eect of scopolamine F 1,17 =23.27 P=0.0002). The eect of scopolamine was indipendent of the training day (time6scopolamine F=2.09 P=0.11).
Overall ANOVA examining the eects of the combination of 1.0 mg kg 71 S 15535 or 2 ml kg 71 saline s.c. and 1.0 mg 0.5 ml 71 WAY 100635 or 0.5 ml saline injected into the DR in intrahippocampal scopolamine-treated rats showed a nonsigni®cant three-way interaction (time6S 155356WAY 100635, F=1.5 P=0.23) but a signi®cant two-way interaction between S 15535 and WAY 100635 (F 1,30 =12.41 P=0.0014).
The histograms in Figure 3B present the results as means+s.e.mean of the ®ve training sessions. The post-hoc Tukey's test indicated that control rats treated with saline in the hippocampus had signi®cantly better discriminative accuracy than those given scopolamine in the hippocampus (P50.05). Scopolamine-treated rats injected with S 15535 made signi®cantly more correct choices than those injected with saline (P50.05; Tukey's test) and rats treated with S 15535+WAY 100635 in the DR had signi®cantly worse choice accuracy than those injected with S 15535+saline in DR (P50.05; Tukey's test). Injection of WAY 100635 into the DR by itself did not modify choice accuracy of scopolaminetreated rats (P40.05; Tukey's test).
The results on choice latency are shown in Figure 3C . Oneway ANOVA comparing control rats given saline or scopolamine in the hippocampus showed the drugs had no signi®cant eect on choice latency (main eect scopolamine, F 1,17 =1.98 P=0.17; time6scopolamine, F=1.45 P=0.24) ( Figure 3C ). In both groups choice latencies signi®cantly declined with training (time, F=5.55 P=0.003).
Overall statistical analysis on scopolamine-treated rats showed no signi®cant three-way (time6WAY 1006356S 15535, F=2,13 P=0.10) or two-way interactions between WAY 100635 and S 15535 (F 1,30 =0.20 P=0.65) or any signi®cant main eect of WAY 100635 (F 1,30 =3.04 P=0.09) or S 15535 (F 1,30 =2,27 P=0.14) but there was a signi®cant main eect of time (F=10.2 P=0.0001) ( Figure 3C ). WAY 100635 or S 15535, or the two combined, had no eect on errors of omission in intrahippocampal scopolamine-treated rats (data not shown).
Discussion
As previously found with the other ligands of 5-HT 1A receptors WAY 100135 (Carli et al., 1995b) and WAY 100635 (Carli et al., 1997a) , in the present study S 15535 0.3 and 1 mg kg 71 s.c. had no eect on the performance of the rat in the two-platform spatial discrimination task, but 1 mg kg 71 signi®cantly antagonized the impairment of choice accuracy caused by scopolamine 4 mg ml 71 infused into the dorsal hippocampus.
At 0.3 mg kg 71 S 15535 showed a non signi®cant tendency to antagonize the eect of scopolamine.
Previous studies in our laboratory suggest that blockade of postsynaptic 5-HT 1A receptors prevents the de®cit of spatial learning caused by intrahippocampal scopolamine in the twoplatform discrimination task. This is clearly shown by the fact that direct blockade of 5-HT 1A receptors in the dorsal hippocampus prevented the de®cit of spatial learning caused by infusing scopolamine in that brain region (Carli et al., 1995b) , whereas blockade of 5-HT 1A autoreceptos in the DR had no eect on the performance of the rat or on the impairment caused by intrahippocampal scopolamine (Carli et al., 1998) .
Although systemically administered S 15535 may prevent the scopolamine-induced de®cit in spatial learning by blocking postsynaptic 5-HT 1A receptors, this compound is a highly active agonist in tests of 5-HT 1A autoreceptor-mediated activity (Millan et al., 1994) . Thus, in view of our recent ®nding that stimulation of presynaptic 5-HT 1A receptors in the dorsal raphe did not aect the performance of the rat but antagonized the impairment of choice accuracy caused by intrahippocampal scopolamine (Carli et al., 1998) , we examined whether 5-HT 1A receptors in the DR were involved in the eect of S 15535.
In a previous study (Carli et al., 1998) WAY 100635 injected into the DR at 1.0 mg 0.5 ml 71 had no eect on rats' performance or on the impairment of choice accuracy caused by intrahippocampal scopolamine but completely prevented 1.0 mg 0.5 ml 71 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT 1A receptor agonist, antagonizing the scopolamine-induced de®cit when administered in the DR. We therefore used the same condition to clarify the role of presynaptic 5-HT 1A receptors in the eect of S 15535.
In agreement with our previous ®ndings (Carli et al., 1998 ), 1.0 mg 0.5 ml 71 WAY 100635 injected into the DR did not aect choice accuracy and latency or errors of omission, or modify the eect of intrahippocampal scopolamine. This is in line with previous ®ndings that WAY 100635 by itself had no eect on extracellular 5-HT (Gurling et al., 1994; Invernizzi et al., 1997) , con®rming that somatodendritic 5-HT 1A receptors are not tonically activated by endogeneous levels of 5-HT (Gartside et al., 1995; Invernizzi et al., 1996) . Nevertheless, WAY 100635 completely antagonized the eect of systemically administered S 15535 on scopolamine-induced impairment of choice accuracy. Thus presynaptic 5-HT 1A receptors clearly appear to be involved in the ability of S 15535 to counteract the impairment of spatial learning caused by scopolamine.
Although blockade of postsynaptic 5-HT 1A receptors may contribute to this eect, at the dose used in the present study the drug very likely modi®ed the eect of scopolamine mainly by acting on presynaptic 5-HT 1A receptors. In line with this are ®ndings by Millan et al. (1997) that at doses as low as 0.3 mg kg 71 s.c. S 15535 reduced extracellular 5-HT levels in the rat hippocampus, a result re¯ecting its agonist properties at 5-HT 1A autoreceptors, whereas higher doses of S 15535 were needed to block postsynaptic 5-HT 1A receptor-mediated responses (Millan et al., 1994) .
At the same doses as in the present study S 15535 showed anxiolytic-like activity in various rat models (Millan et al., 1997; Cervo et al., 1997) . It is unlikely that this activity interfered with rats' performance since S 15535 had no eect on motivational indices such as choice latency and errors of omission that one would expect to be aected by an anxiolytic eect in an aversively motivated task. Moreover, anxiolytic drugs such as benzodiazepines cause an impairment of spatial learning in a water maze (McNaughton & Morris, 1987) . In view of recent suggestions that enhanced anxiety may contribute to learning de®cit following cholinergic blockade (Smythe et al., 1996; Leri & Franklin, 1998 ) S 15535 might perhaps reduce the de®cit caused by scopolamine, in part, through its anxiolytic activity. Stimulation of 5-HT 1A receptors in the DR caused anxiolytic-like eects in various models (Higgins et al., 1988; Handley, 1995) . Although further studies are necessary to clarify this point, the present ®ndings and our own results with 8-OH-DPAT injected into the DR (Carli et al., 1998) add new information on the functional output of stimulating 5-HT 1A receptors in this brain region. Reductions of 5-HT transmission in terminal regions are presumably involved in the anxiolytic and memory-enhancing eects of compounds stimulating 5-HT 1A autoreceptors.
The fact that S 15535, as previously found with 8-OH-DPAT administered into the DR had no eect on spatial performance (Carli et al., 1998) but reduced 5-HT transmission in terminal regions (Invernizzi et al., 1991) con®rms that 5-HT neurons originating from the DR have no direct eect on the acquisition of spatial memory but modulate the eect of other systems more directly involved.
It is unlikely that 5-HT neurones originating in the nucleus raphe medianus that innervate the hippocampal formation were indirectly involved since 8-OH-DPAT injections in this nucleus, unlike those in the DR, did not attenuate the learning de®cit caused by intrahippocampal scopolamine and actually caused an impairment of choice accuracy in the two-platform spatial discrimination task (unpublished results).
The entorhinal cortex provides a major cortical input to the hippocampus through a pathway using glutamate as neurotransmitter (Iijima et al., 1996; see Francis et al., 1993) and selective lesions in this area cause a selective de®cit in an allocentric memory task (Holscher & Schmidt, 1994) . Super®cial cells of the entorhinal cortex are inhibited by serotonin (Schmitz et al., 1995) and are preferentially innervated by serotonergic neurons in the dorsal raphe (Jacobs & Azmitia, 1992) . S 15535 by stimulating 5-HT 1A receptors in the DR may reduce 5-HT transmission in this region. The reduction of a serotonergic inhibitory in¯uence to the entorhinal cortical cells, may facilitate the transfer of excitatory information from the entorhinal cortex to the hippocampus and thus compensate the loss of cholinergic input to the hippocampal pyramidal cells. This hypothesis is currently under investigation in our laboratory.
Whatever the neuronal mechanism and brain region involved, S 15535 and probably other partial agonists at central 5-HT 1A receptors may oer a novel approach for the symptomatic treatment of memory disturbances in man, including Alzheimer's disease where a close correlation has been found between the reduction in acetylcholine markers in the hippocampus and behavioural de®cit (Katzman et al., 1986) .
